Therapeutic Area | MeSH |
---|---|
nervous system diseases | D009422 |
Brand Name | Status | Last Update |
---|---|---|
sabril | New Drug Application | 2024-01-09 |
vigabatrin | ANDA | 2024-09-30 |
vigabatrin for oral solution | ANDA | 2024-04-22 |
vigadrone | ANDA | 2024-11-18 |
vigafyde | New Drug Application | 2025-02-27 |
vigpoder | ANDA | 2024-12-13 |
Indication | Ontology | MeSH | ICD-10 |
---|---|---|---|
epilepsy | EFO_0000474 | D004827 | G40.9 |
infantile spasms | EFO_1000643 | D013036 | G40.82 |
complex partial epilepsy | EFO_1000877 | D017029 | — |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Seizures | D012640 | — | G40.4 | — | — | — | 2 | 1 | 3 |
Spasm | D013035 | — | M62.83 | — | — | — | 1 | 1 | 2 |
Infantile spasms | D013036 | EFO_1000643 | G40.82 | — | — | — | 1 | 1 | 2 |
Tuberous sclerosis | D014402 | — | Q85.1 | — | — | — | 1 | — | 1 |
Drug common name | Vigabatrin |
INN | vigabatrin |
Description | Vigabatrin is a gamma-amino acid having a gamma-vinyl GABA structure. It is an irreversible inhibitor of gamma-aminobutyric 664 acid transaminase It has a role as an anticonvulsant and an EC 2.6.1.19 (4-aminobutyrate--2-oxoglutarate transaminase) inhibitor. |
Classification | Small molecule |
Drug class | gabamimetics |
Image (chem structure or protein) | ![]() |
Structure (InChI/SMILES or Protein Sequence) | C=CC(N)CCC(=O)O |
PDB | — |
CAS-ID | 60643-86-9 |
RxCUI | — |
ChEMBL ID | CHEMBL89598 |
ChEBI ID | 63638 |
PubChem CID | 5665 |
DrugBank | DB01080 |
UNII ID | GR120KRT6K (ChemIDplus, GSRS) |